The goal of this Randomized Controlled Trial is to to compare the effect of Risperidone vs Aripiprazole in terms of change in serum Glutathione level in patients with Autism Spectrum Disorder over a period of 6 weeks. The main questions it aims to answer are: 1. (Primary Outcome) Change in serum Glutathione levels following 6 weeks of intervention in both the arms 2. (Secondary Outcomes) Change in serum superoxide dismutase (SOD) levels following 6 weeks of intervention. Change in ISAA score following 6 weeks of intervention. Change in ABC-C score following 6 weeks of intervention. • Adverse events reported in both groups Details of intervention- One arm of the study population to get Risperidone 1mg/day for a total duration of 6 weeks and another arm to get Aripiprazole 2mg/day for a total duration of 6 weeks. Baseline assessment of Serum Glutathione, Serum SOD, ISAA scale, ABC-C scale will be done and same will be assesssed at 6 weeks follow up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
42
The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
Change in serum Glutathione levels following 6 weeks of intervention in both the arms
Change in serum Glutathione levels following 6 weeks of intervention in both the arms
Time frame: 6 weeks
Change in serum superoxide dismutase (SOD) levels following 6 weeks of intervention.
Time frame: 6 weeks
Change in ISAA score following 6 weeks of intervention.
Time frame: 6 weeks
Change in ABC-C score following 6 weeks of intervention. •
Time frame: 6 weeks
Adverse events reported in both groups
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.